Glaukos Corporation Stock News

Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix (OFIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

ALISO VIEJO, Calif.

Needham initiated coverage on Glaukos Corp (NYSE: GKOS) with a price target of $66 and a Buy rating. The analyst writes that GKOS has lost minimally invasive glaucoma surgery (MIGS) market share

Upgrades For Bank of New York Mellon Corp (NYSE:BK), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, Bank of New York Mellon had an EPS of $1.03, compared to year-ago

Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.

Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.

Gainers IMARA Inc. (NASDAQ: IMRA) jumped 74.8% to settle at $2.01 on Wednesday after the company announced it entered into an asset purchase agreement with Cardurion Pharmaceuticals to sell tovinontr

Investors were cheered by the latest update from the lab.